Research programme: therapeutic agents and companion diagnostics - Celgene Corporation/IMIDomics
Latest Information Update: 28 Jun 2021
At a glance
- Originator Celgene Corporation; IMIDomics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Diagnostic agents
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus; Ulcerative colitis
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Crohn's-disease in USA
- 28 Jun 2021 No recent reports of development identified for research development in Crohn's-disease(Diagnosis) in USA
- 28 Jun 2021 No recent reports of development identified for research development in Psoriasis in USA